NAPROXEN (na-prox'en) Apo-Naproxen , EC-Naprosyn, Naprelan, Naprosyn, Naxen , Novonaprox NAPROXEN SODIUM Aleve, Anaprox, Anaprox DS Classifications: central nervous system agent; analgesic; nsaid; antipyretic Prototype: Ibuprofen Pregnancy Category: B |
200 mg, 250 mg, 375 mg, 500 mg tablets; 375 mg, 500 mg sustained release tablets
Propionic acid derivative. NSAID with properties similar to those of other propionic acid derivatives, e.g., ibuprofen, fenoprofen, ketoprofen. Mechanism of action thought to be related to inhibition of prostaglandin synthesis.
Analgesic, antiinflammatory and antipyretic effects; also inhibits platelet aggregation and prolongs bleeding time but does not alter whole blood clotting, prothrombin time or platelet count. Cross-sensitivity with other NSAIDs has been reported.
Antiinflammatory and analgesic effects in symptomatic treatment of acute and chronic rheumatoid arthritis, juvenile arthritis (naproxen only), and for treatment of primary dysmenorrhea. Also management of ankylosing spondylitis, osteoarthritis, and gout.
Paget's disease of bone, Bartter's syndrome.
Active peptic ulcer; patients in whom asthma, rhinitis, urticaria, bronchospasm, or shock is precipitated by aspirin or other NSAIDs. Safety during pregnancy (category B), lactation, or in children <2 y is not established.
History of upper GI tract disorders; impaired kidney, liver, or cardiac function; patients on sodium restriction (naproxen sodium); low pretreatment Hgb concentration; fluid retention, hypertension, heart failure; older adults.
Note: 275 mg naproxen sodium = 250 mg naproxen Inflammatory DiseaseAdult: PO 250500 mg b.i.d. (max: 1000 mg/d naproxen, 1100 mg/d naproxen sodium); Naprelan is dosed q.d. Child: PO >2 y, 1015 mg/kg/d in 2 divided doses (max: 1000 mg/d) Mild to Moderate Pain, Dysmenorrhea Adult: PO 500 mg followed by 200250 mg q68h prn up to 1250 mg/d Child: PO >2 y, 57 mg/kg q812h |
Transient elevations in BUN and serum alkaline phosphatase may occur. Naproxen may interfere with some urinary assays of 5-HIAA and may cause falsely high urinary 17-KGS levels (using m-dinitrobenzene reagent). Naproxen should be withdrawn 72 h before adrenal function tests.
Assessment & Drug Effects
Patient & Family Education